It has been five years since the first biosimilar launched in the United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients
Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team cult
In the first of a two part series, IQVIA's Sarah Rickwood covers nine key trends and events that will affect the global healthcare and pharmaceutical industries in 2021.
